In summary, our study confirmed two PALB2 recurrent mutations, c.172_175delGA and c.509_510delGA, in BRCA1/2-mutation negative breast and/or ovarian cancer patients from Poland. This evidence concerns the gene BRCA1 and ovarian carcinoma.